Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FQSU8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $16,584.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, awarded on December 2, 2025, with an ultimate completion date of December 23, 2025, was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract awarded on November 13, 2025, that positions the company as a critical pharmaceutical supplier for Department of Defense healthcare operations worldwide.
The PPV-G GEN V contract, part of the broader $30.3 billion Defense Logistics Agency pharmaceutical acquisition strategy, authorizes the issuance of firm fixed-price delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support recurring medical supply needs of military healthcare facilities globally. DMS Pharmaceutical Group's established performance across numerous delivery orders and its extensive product portfolio—encompassing oncology treatments, immunosuppressants, specialty pharmaceuticals, vaccines, and routine medications—demonstrates its capability to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system. The company operates without identified subcontractor relationships and has maintained consistent contract performance across multiple therapeutic categories since its registration in the System for Award Management in July 2001.
Quick answers
Who was awarded contract SPE2DR26FQSU8?
SPE2DR26FQSU8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 2, 2025.
How much is contract SPE2DR26FQSU8 worth?
The government has obligated $16,584 on SPE2DR26FQSU8.
Is contract SPE2DR26FQSU8 an order under another contract?
Yes. SPE2DR26FQSU8 is a delivery order under SPE2DR25D9214, an indefinite delivery contract.
Was contract SPE2DR26FQSU8 competed?
The extent of competition for SPE2DR26FQSU8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award